AMIX
failedAutonomix Medical, Inc.
Price Chart
Gap Information
Score Analysis
Model 1: Rerate Score
Model 2: Trade Probability
AI Thesis
Autonomix Medical's 54% gap-up on 36.7x normal volume signals a potentially transformative development update rather than traditional earnings-driven repricing. As a development-stage medical device company focused on a novel catheter-based platform for treating pancreatic cancer pain via nerve ablation, any meaningful clinical milestone, FDA interaction (such as Breakthrough Device designation or IDE approval), or proof-of-concept data would fundamentally alter the risk/reward profile. The sheer volume spike suggests institutional or sophisticated healthcare investors are positioning ahead of a definable regulatory or clinical catalyst, not merely chasing momentum. The stock has continued running past the open ($4.30) to $5.41, indicating sustained buying pressure beyond the initial gap, which is typically a bullish signal that the market is digesting material positive information rather than a short-lived squeeze. However, investors should recognize this is a micro-cap, pre-revenue or early-revenue story where volatility is extreme and liquidity thin. The rerating case rests entirely on the company's ability to execute on its clinical and regulatory roadmap — if the gap was driven by a legitimate fundamental catalyst (trial data, regulatory milestone), the stock could see sustained upside as the addressable market opportunity in pancreatic cancer pain management is substantial and underserved.
Analyzed by rerate-v2+glm-5.2 · Jul 29, 2026
Catalysts
- FDA regulatory progress — Breakthrough Device designation, IDE approval, or pre-submission feedback for pancreatic nerve ablation system
- Positive clinical or preclinical data demonstrating safety/efficacy of catheter-based nerve ablation platform
- Strategic partnership or licensing deal with a larger medtech or oncology-focused company
- Expansion of platform technology beyond pancreatic cancer to other visceral pain indications
- Successful capital raise on improved terms to fund pivotal trial execution
Risks
- Pre-revenue or minimal revenue company — extreme cash burn and likely need for dilutive financing within 12-18 months
- Micro-cap with very low float — gap could partially reverse on thin liquidity and lack of institutional support
- Regulatory risk — FDA clinical hold, trial delays, or adverse safety events could crater the stock
- No proven commercialization track record — execution risk on manufacturing, reimbursement coding, and market access
- Single-indication dependency — if pancreatic cancer pain application fails, the platform thesis collapses
- Stock is well below 50-day SMA ($6.80), suggesting prior significant sell-off — this gap may be a relief rally in a broader downtrend rather than a fundamental inflection
Technical Setup
Forward Returns
Outcomes calculated Aug 11, 2026
Post-Gap Validation — 5-Day Follow-Through
Day-by-Day Price Action
| Day | Close | High | Low | Volume |
|---|---|---|---|---|
| Day 1 | $3.59 | $4.37 | $3.37 | 1.31M |
| Day 2 | $3.44 | $3.88 | $3.02 | 510.4K |
| Day 3 | $3.65 | $3.79 | $3.07 | 226.7K |
| 📍 Day 4 | $19.50 | $24.68 | $5.24 | 120.03M |
| Day 5 | $12.10 | $18.69 | $11.62 | 14.42M |
Signal Breakdown
Gap 75% filled — price gave back most of the post-earnings gap
Volume sustained — only -1000% decline suggests continued accumulation
Higher highs with peak close on day 4 — continued buying interest
Drew down 44.2% from gap close — significant give-back
No fundamental data to evaluate beat quality
Analysis updated Aug 11, 2026